Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Total revenues	$ 0	$ 0	$ 0	$ 0
Total cost of revenue	0	0	0	0
Gross profit (loss)	0	0	0	0
Research and development expense	1,541,000	1,657,000	4,601,000	4,800,000
Selling, general and administrative expense	1,501,000	1,958,000	4,696,000	5,109,000
Operating loss	(3,105,000)	(4,596,000)	(9,163,000)	(14,077,000)
Other income (expense):
Warrant revaluation income (expense)	265,000	4,981,000	591,000	(4,742,000)
Derivative revaluation income (expense)	87,000	(254,000)	266,000	287,000
Interest expense	(194,000)	(273,000)	(575,000)	(641,000)
Other income, net	88,000	27,000	227,000	33,000
Loss before income taxes	(2,859,000)	(115,000)	(8,654,000)	(19,140,000)
Income taxes	0	0	0	0
Net loss	(2,859,000)	(115,000)	(8,654,000)	(19,140,000)
Dividend paid in-kind to preferred stockholders	(85,000)	(82,000)	(250,000)	(182,000)
Deemed dividend on preferred stock (see Note 10)	(130,000)	(111,000)	(377,000)	(3,981,000)
Net loss attributable to common stockholders	$ (3,074,000)	$ (308,000)	$ (9,281,000)	$ (23,303,000)
Net loss:
Basic (usd per share)	$ (0.33)	$ (0.10)	$ (1.31)	$ (7.92)
Diluted (usd per share)	$ (0.33)	$ (0.12)	$ (1.31)	$ (7.92)
Weighted average number of common shares outstanding:
Basic (shares)	9,234,869	2,945,035	7,107,678	2,942,202
Diluted (shares)	9,234,869	2,948,290	7,107,678	2,942,202
Affiliated Entity
Research and development expense	$ 63,000	$ 981,000	$ (134,000)	$ 4,168,000